Pediatric Palliative Symptom Categories for (e)PROM in Specialized Pediatric Palliative Home Care.

J Pain Symptom ManageJul 16, 2026 (epub)
Clinical ResearchPediatrics

Rebekka Hocher, Nora Ruthke, Theresa Sophie Busse et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review developed a child-specific electronic patient-reported outcome measure (ePROM) tool for assessing symptom burden in pediatric palliative home care (PPHC). Involving 63 patients, the Pediatric Palliative Symptom Categories (PPSC) identified 37 relevant symptom categories, demonstrating a broader scope than existing adult-derived instruments. The tool's accuracy was confirmed, though adjustments were needed based on user feedback.

Key findings

  • The Pediatric Palliative Symptom Categories (PPSC) identified 37 symptom categories relevant to pediatric palliative home care.
  • The PPSC showed high consistency with existing instruments but covered a wider range of symptoms.
  • User feedback indicated necessary adjustments in language and scope for the PPSC.

Why it matters

The development of a tailored ePROM tool for pediatric palliative care addresses the unique symptom management needs of children, enhancing the ability to monitor and respond to their health status effectively.

Source

PubMed · PMID 42463062

Published in J Pain Symptom Manage. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.